Friday, 21 Sep 2018

You are here

Thiopurines and Anti-TNF drugs in IBD Associated with Increased Lymphoma Risk

JAMA presents a French report on the cancer risk of thiopurine or tumor necrosis factor inhibitor (TNFi) use in adult patients with inflammatory bowel disease (IBD) and finds a raised risk for lymphoma in IBD compared to those not treated with these agents.  (Citation source https://buff.ly/2z04f9h)

Using national French National Health Insurance databases, they studied adults with IBD between 2009-2013, with follow-up through 2015; specifically looking for lymphomas associated with thiopurines and anti-TNF agents.

The study included 189,289 patients (median age 43 years) with a medial follow up of 6.7 years. Cohorts included those never exposed (n 123 069), thiopurine monotherapy exposed (n 50405), TNFi exposed (30294), and combination therapy exposed (14229).

For those drug exposed, there were a total of 336 lymphomas and the incidence rate was 0.26 per 1000 person-years (95% CI, 0.23-0.29), The drug-related risks were:

  • thiopurine monotherapy - adjusted hazard ratio [aHR] = 2.60; 95% CI, 1.96-3.44 (P < .001)
  • anti-TNF monotherapy - aHR = 2.41; 95% CI, 1.60-3.64 (P < .001)
  • combination therapy - aHR = 6.11; 95% CI, 3.46-10.8 (P < .001).

Lymphoma subtypes included nonfollicular lymphoma (130 cases, 39%), diffuse large B-cell lymphoma (83 cases); Hodgkin lymphoma (55 cases, 16%); and follicular lymphoma (41, 12%). Hodgkin lymphoma made up 14% of all lymphomas among unexposed patients, 19% among patients exposed to thiopurines, 19% in those exposed to TNF blockers, and 43% in those exposed to combination therapy.

Editor's note: these findings are in line with what has been reported for TNFi previously by the FDA and is reflected in the product label for each TNFi. What is unique here is that in patients with rheumatoid arthritis, the rate of lymphoma was higher (2-6 fold higher) when comparing patients on drug to those in the normal population; but was equal to other RA patients not taking TNFi.  These studies show that in IBD the lymphoma risk was roughly 2.5 fold higher when comparing IBD patient on TNFi or thiopurine to those not taking these aggressive therapies.  While this most likely represents the channeling bias of those with more aggressive disease receiving more aggressive therapy. The authors noted that the benefits of these agents in IBD must be weighed against the absolute risk of < 1 lymphoma per 1000 patient-years of exposure.

In IBD patients the use of thiopurine monotherapy or anti-TNF monotherapy was associated with a small but statistically significant increased risk of lymphoma compared with exposure to neither medication, and this risk was higher with combination therapy than with each of these treatments used alone. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

New BSR Guidelines on Biologic Safe Use with Inflammatory Arthritis

The British Society of Rheumatology has produced a set of NICE accredited guidelines for the use of biologic therapies in patients with inflammatory arthritis.

It addresses safety recommendations for all biologic therapies approved by the National Institute for Health and Care Excellence (NICE) up to June 2016, for use in all inflammatory arthritides [RA, PsA and axial SpA (SpA) including AS].

The Safety of Paternal Exposure to DMARDs and Biologics

Pregnancy and drug safety is a complex issue, often with limited informatoin about maternal drug exposure on the offspring. Greater uncertainty exists when considering whether paternal exposure may also influence fetal outcomes.

A systematic review examined the effect of disease modifying anti-rheumatic drugs (DMARDs) on male fertility and if peri-conception (within 3 months) paternal exposure was detrimental to fetal outcomes.

2018-2019 ACIP Recommendations for Seasonal Influenza Vaccination

The current issue of the CDC's MMWR reviews the new seasonal recommendations for vaccination against influenza. This is an update to the previous recommendations of the Advisory Committee on Immunization Practices (ACIP). 

Health Secretary Azar Eyes Rebate Reform

Reuters reports that the U.S. Health and Human Services Secretary Alex Azar had declared his agency has the authority to eliminate rebates on prescription drug purchases, a key element in the administration’s plan to lower prescription medicine costs.

Azar has said rebates created a perverse incentive to continuously raise drug prices.

Hydroxychloroquine Being Over-Dosed with New Guidelines?

Hydroxychloroquine retinopathy prevention guidelines have revised from ideal body weight-based dosing to actual body weight-based dosing; the question remains whether these have been adopted in clinical practice. A database of nearly 21,000 new HCQ users from a UK general population database studied HCQ dosing and use between 2007 and 2016. Specifically they examined whether users were subjected to excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW).